Author(s): Chaudhari U, Romano P, Mulcahy L, Dooley L, B aker D, et al.
Background: Currently available treatments for moderate to severe psoriasis are either incompletely effective in some patients, or are associated with toxic effects. Since tumour necrosis factor alpha (TNF-alpha) is thought to have a role in the pathogenesis of psoriasis, we did a double-blind, randomised trial to assess the clinical benefit and safety of infliximab-a monoclonal antibody against TNF-alpha.
Methods: 33 patients with moderate to severe plaque psoriasis were randomly assigned intravenous placebo (n=11), infliximab 5 mg/kg (n=11), or infliximab 10 mg/kg (n=11) at weeks 0, 2, and 6. Patients were assessed at week 10 for the primary endpoint (score on the physician's global assessment [PGA]). Analysis was by intention to treat.
Findings: Of the 33 patients enrolled, three dropped out. Nine of 11 (82%) patients in the infliximab 5 mg/kg group were responders (good, excellent, or clear rating on PGA), compared with two of 11 (18%) in the placebo group (difference 64% [95% CI 20-89], p=0.0089), and ten of 11 (91%) patients in the infliximab 10 mg/kg group were responders (difference from placebo 73% [30-94], p=0.0019). The median time to response was 4 weeks for patients in both infliximab groups. There were no serious adverse events, and infliximab was well tolerated.
Interpretation: In this controlled trial, patients receiving the anti-TNF-alpha agent infliximab as monotherapy experienced a high degree of clinical benefit and rapid time to response in the treatment of moderate to severe plaque psoriasis compared with patients who received placebo. These findings suggest that TNF-alpha has a pivotal role in the pathogenesis of psoriasis.
Referred From: https://pubmed.ncbi.nlm.nih.gov/11410193/
Author(s): Ameglio F, Bonifati C, Fazio M, Mussi A, Trento E, et al.
Author(s): Krueger J, Bowcock A
Author(s): Mehlis SL, Gordon KB
Author(s): Bos JD, de Rie MA, Teunissen MB, Piskin G
Author(s): Lowes MA, Bowcock AM, Krueger JG
Author(s): Prens EP, Benne K, van DJ, Bakkus M, Brakel K, et al.
Author(s): Mangalam AK, Veena T, David CS
Author(s): Johnson DR
Author(s): Arican O, Aral M, Sasmaz S, Ciragil P
Author(s): Jacob SE, Nassiri M, Kerdel FA, Vincek V
Author(s): Pietrzak A, Kozioł-Montewka M, Lecewicz-Toruń B, Krasowska D
Author(s): Szepietowski JC, Bielicka E, Nockowski P, Noworolska A, Wasik F
Author(s): Krueger JG
Author(s): Pillai S, Bikle DD, Eessalu TE, Aggarwal BB, Elias PM
Author(s): Cesare DC, Meglio PD, Nestle FO
Author(s): Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, et al.
Author(s): Makhatadze NJ
Author(s): Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M
Author(s): Mak R, Hundhausen C, Botti E, Laggner U, Grys K, et al.
Author(s): Murphy M, Philip K, Grant- Kels JM